Helping T cells in Type 1 diabetes
Modulating pathogenic T cells in Type 1 diabetes
This work explores new ways to treat, delay, or prevent Type 1 diabetes by understanding how certain immune cells behave.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11094117 on NIH RePORTER |
What this research studies
This project aims to develop new treatments for Type 1 diabetes, building on past successes that led to the first FDA-approved drug to delay the disease. Researchers are looking closely at how this drug affects specific immune cells, called CD8+ T cells, and why some patients respond better than others. They are also trying to understand what makes the benefits of the treatment last for a long time in some individuals. By using samples from previous successful clinical trials, the team hopes to uncover these important mechanisms to improve future therapies.
Who could benefit from this research
Good fit: Ideal candidates for this type of research would be individuals with Type 1 diabetes or those at risk of developing it, who might participate in future clinical trials.
Not a fit: Patients who do not have Type 1 diabetes or are not at risk for it would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective and personalized immune therapies to treat, delay, or prevent Type 1 diabetes.
How similar studies have performed: Previous work from this grant has already led to the FDA approval of a drug that delays Type 1 diabetes, demonstrating significant success with similar approaches.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Herold, Kevan C — Yale University
- Study coordinator: Herold, Kevan C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.